The Critical Path for Parkinson's Consortium Approach to Developing Consensus Recommendations for Neuroimaging Biomarkers Appropriate for use in Parkinson's Disease Drug Development

被引：0
|
作者：
Muller, M.
Comley, R.
Eberling, J.
Kazmi, H.
Kustermann, T.
Maguire, P.
Marek, K.
McGinnity, C.
Minchik, M.
Parker, C.
Passamonti, L.
Rousset, O.
Russell, D.
Salinas, C.
Seibyl, J.
Sivakumaran, S.
Stoessl, J.
Strafella, A.
Tosun-Turgut, D.
Wang, Y.
Stephenson, D.
Pagano, G.
机构：
来源：
MOVEMENT DISORDERS | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1590
引用
收藏
页码：S701 / S701
页数：1
相关论文
共 50 条
  • [21] Recent advances in biomarkers for Parkinson's disease focusing on biochemicals, omics and neuroimaging
    Ren, Rutong
    Sun, Yi
    Zhao, Xin
    Pu, Xiaoping
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2015, 53 (10) : 1495 - 1506
  • [22] Critical path for Parkinson's, I: Data sharing and regulatory science in catalyzing innovation for Parkinson's disease
    Romero, K.
    Burn, D.
    Hu, M.
    Yarnell, A.
    Gray, C. Williams
    Marek, K.
    Grosset, D.
    Sutherland, M.
    Isaac, M.
    Bhattaram, A.
    Sinha, V.
    Gordon, M. F.
    Muglia, P.
    Slicker, L.
    Hirst, W.
    Facheris, M.
    Posener, J.
    Bani, M.
    Corrigan, B.
    Schindler, R.
    Tsai, K.
    Nicholas, T.
    Cedarbaum, J.
    Gallagher, J.
    Ford, S.
    Avilex, E.
    Kern, V.
    Arneric, S.
    Stephenson, D.
    Roach, A.
    MOVEMENT DISORDERS, 2016, 31 : S673 - S673
  • [23] Spanish expert consensus on the use of safinamide in Parkinson's disease
    Valldeoriola, F.
    Grandas, F.
    Arbelo, J. M.
    Blazquez Estrada, M.
    Calopa Garriga, M.
    Campos-Arillo, V. M.
    Garcia Ruiz, P. J.
    Gomez Esteban, J. C.
    Leiva Santana, C.
    Martinez Castrillo, J. C.
    Mir, P.
    Salvador Aliaga, A.
    Vivancos Matellano, F.
    Yanez Bana, R. M.
    NEUROLOGIA, 2021, 36 (09): : 666 - 672
  • [24] Path analysis of biomarkers for cognitive decline in early Parkinson's disease
    Gramotnev, Dmitri K.
    Gramotnev, Galina
    Gramotnev, Alexandra
    Summers, Mathew J.
    PLOS ONE, 2022, 17 (05):
  • [25] Inferring microarray datasets reveals critical biomarkers and potential drug targets of Parkinson's disease
    Bhardwaj, Anuradha
    Obaid, Ahmad A.
    Khan, Anmar Anwar
    Singh, Mahendra P.
    Jalal, Mohammed M.
    Mohammedsaleh, Zuhair M.
    Moawadh, Mamdoh S.
    Alsanie, Walaa F.
    Alamri, Abdulhakeem S.
    Alhomrani, Majid
    Alsharif, Abdulaziz
    Singh, Sandeep Kumar
    NEUROLOGY ASIA, 2024, 29 (04) : 1053 - 1061
  • [26] A survey of antidepressant drug use in Parkinson's disease
    Richard, IH
    Kurlan, R
    NEUROLOGY, 1997, 49 (04) : 1168 - 1170
  • [27] Role of imaging in drug development for Parkinson's disease
    Brooks, David J.
    FUTURE NEUROLOGY, 2006, 1 (03) : 335 - 342
  • [28] RNA biomarkers of Parkinson's disease: developing tools for novel therapies
    Hennecke, Gerrit
    Scherzer, Clemens R.
    BIOMARKERS IN MEDICINE, 2008, 2 (01) : 41 - 53
  • [29] The development of visual neuroimaging research of acupuncture in the treatment of Parkinson's disease
    Yuan Yang
    Suhua Miao
    Rongsong Zhou
    Yu Ma
    Yuqi Zhang
    Brain Science Advances, 2019, 5 (03) : 161 - 168
  • [30] Parkinson's Disease - Challenges in New Drug Development
    Babic, Tomislav
    Mahovic, Darija
    COLLEGIUM ANTROPOLOGICUM, 2008, 32 (04) : 1275 - 1281
12345